CRD 102 - CardioraAlternative Names: CRD-102 - Cardiora
Latest Information Update: 17 Jun 2016
At a glance
- Originator Cardiora
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Heart failure
Most Recent Events
- 16 Jun 2016 Preclinical trials in Heart failure in USA (PO) before June 2016 (Cardiora website, June 2016)
- 16 Jun 2016 Cardiora plans to file an IND application with the US FDA for Heart faliure in the fourth quarter of 2016 (Cardiora website, June 2016)
- 12 May 2016 Cardiora initiates enrolment in a phase Ib trial for Heart faliure in Australia (ACTRN12616000619448p)